Detalhe da pesquisa
1.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
2.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
3.
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
J Clin Oncol
; 42(5): 550-561, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096461
4.
Npr2, yeast homolog of the human tumor suppressor NPRL2, is a target of Grr1 required for adaptation to growth on diverse nitrogen sources.
Eukaryot Cell
; 9(4): 592-601, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20154027
5.
Identification of a conserved F-box protein 6 interactor essential for endocytosis and cytokinesis in fission yeast.
Biochem J
; 420(2): 169-77, 2009 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19243310
6.
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Leukemia
; 34(2): 522-532, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462735
7.
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Clin Cancer Res
; 25(15): 4634-4643, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053601
8.
Regulation and recognition of SCFGrr1 targets in the glucose and amino acid signaling pathways.
Mol Cell Biol
; 24(20): 8994-9005, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15456873
9.
Grr1-dependent inactivation of Mth1 mediates glucose-induced dissociation of Rgt1 from HXT gene promoters.
Mol Biol Cell
; 14(8): 3230-41, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12925759